Millennium Management LLC Has $1.63 Million Holdings in Kronos Bio, Inc. (NASDAQ:KRON)

Millennium Management LLC cut its holdings in shares of Kronos Bio, Inc. (NASDAQ:KRON) by 16.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,716,501 shares of the company’s stock after selling 329,302 shares during the quarter. Millennium Management LLC owned 2.84% of Kronos Bio worth $1,631,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Kennedy Capital Management LLC grew its position in Kronos Bio by 8.7% during the fourth quarter. Kennedy Capital Management LLC now owns 149,251 shares of the company’s stock worth $142,000 after buying an additional 12,007 shares in the last quarter. Gilead Sciences Inc. acquired a new stake in shares of Kronos Bio during the 4th quarter worth $179,000. Deltec Asset Management LLC acquired a new stake in shares of Kronos Bio during the 4th quarter worth $190,000. Peapod Lane Capital LLC bought a new position in shares of Kronos Bio in the fourth quarter worth $534,000. Finally, Renaissance Technologies LLC raised its stake in Kronos Bio by 19.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,171,808 shares of the company’s stock valued at $1,113,000 after purchasing an additional 192,754 shares in the last quarter. 64.09% of the stock is currently owned by institutional investors and hedge funds.

Kronos Bio Stock Down 1.0%

KRON opened at $0.67 on Tuesday. Kronos Bio, Inc. has a twelve month low of $0.65 and a twelve month high of $1.60. The stock has a market capitalization of $40.76 million, a price-to-earnings ratio of -0.47 and a beta of 1.75. The company has a 50-day simple moving average of $0.77 and a 200 day simple moving average of $0.90.

Kronos Bio (NASDAQ:KRON) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.13). Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%. The firm had revenue of $2.27 million for the quarter, compared to analyst estimates of $1.00 million. Sell-side analysts anticipate that Kronos Bio, Inc. will post -1.36 EPS for the current fiscal year.

Kronos Bio Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.